A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

What is the purpose of this trial?

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.



Eli Lilly and Company

Start Date: 11/30/2018

End Date: 12/02/2019

Last Updated: 05/06/2019

Study HIC#: 2000022550

Get Involved

For more information about this study, contact:
Kirsten Dooley
+1 203-764-8412
kirsten.dooley@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image